TFA Therapeutics (RAJAF) Cash & Current Investments (2020 - 2025)

TFA Therapeutics has reported Cash & Current Investments for 6 years, with the latest figure at $3199.0 in Q4 2025.

• On a quarterly basis, Cash & Current Investments fell 91.42% year-over-year to $3199.0 in Q4 2025; TTM through Dec 2025 was $3199.0, a 91.42% decrease from a year earlier, with the FY2025 full-year figure at $3199.0, down 91.42% from the prior year.
• Cash & Current Investments was $3199.0 for Q4 2025 at TFA Therapeutics, down from $37284.0 in the prior quarter.
• The five-year high for Cash & Current Investments was $126897.0 in Q4 2021, with the low at $3199.0 in Q4 2025.
• Average Cash & Current Investments over 5 years is $36354.0, with a median of $20007.5 recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Cash & Current Investments soared 542.48% in 2021, then tumbled 91.55% in 2022.
• Over 5 years, Cash & Current Investments stood at $126897.0 in 2021, then sank by 91.55% to $10729.0 in 2022, then jumped by 115.34% to $23104.0 in 2023, then soared by 61.37% to $37284.0 in 2024, then sank by 91.42% to $3199.0 in 2025.
• The last three Cash & Current Investments figures came in at $3199.0 (Q4 2025), $37284.0 (Q4 2024), and $23104.0 (Q4 2023), per Business Quant data.